Is Yatharth Hospitals & Trauma Care Services a Good Buy?

Yatharth Hospitals & Trauma Care Services has positioned itself as one of the fastest-growing hospital chains in North India, combining strong revenue visibility, rapid capacity expansion, and strategic international outreach. While the company’s fundamentals appear robust and aligned with long-term growth, certain risks such as rising working capital requirements, promoter pledging, and senior-level resignations need to be acknowledged.

Sustained Revenue Growth Outlook

The company has retained its 30% revenue growth guidance for FY26 and subsequent years, building on FY25 revenues of ₹880 crore. This reflects management’s confidence in the underlying demand for healthcare services, as well as its ability to scale operations efficiently. With healthcare demand continuing to expand across India’s Tier I and Tier II cities, Yatharth’s visibility on topline growth remains a major strength.

Aggressive Expansion of Bed Capacity

Yatharth is also pursuing a structured plan to expand its bed capacity to 3,000 beds by FY28, up from its current 2,300+ beds. This will be achieved through both brownfield expansions and new facilities:

Noida Extension – currently 450 beds (+250 beds planned over the next 2–2.5 years).
Greater Noida – 400 beds (+200 beds planned in 2–2.5 years).
Jhansi-Orchha (305 beds) and Greater Faridabad (200 beds) – both fully operational.
New Delhi facility – inaugurated in July 2025.
Faridabad expansion – to be operational in August 2025, adding 700 beds to the network.
Notably, the Greater Faridabad unit turned net profit positive in Q1FY26 within just one year of operations, underscoring the strong patient inflows and operational efficiency. This milestone boosts confidence that newer facilities can contribute meaningfully to margins and revenue growth from FY26 onwards.

Strong Capital Expenditure and Asset Growth

The company has committed capex guidance of ₹300–310 crore for FY25, with similar investments lined up for FY26 and FY27. This steady investment cycle is supported by a strong balance sheet. Fixed assets rose from ₹442 crore in March 2024 to ₹605 crore in March 2025 (including ₹105 crore in intangibles), representing 37% growth. In addition, capital work-in-progress (CWIP) stood at ₹222 crore as of March 2025, reflecting significant ongoing projects. This consistent capex signals management’s readiness to back expansion with tangible investments in infrastructure.

International Outreach and Patient Diversification

To broaden its patient base, Yatharth has established information centers in Uzbekistan, Tajikistan, Mauritius, Tanzania, and Kenya, while also forming tie-ups with Ministries of Health in Iraq and Congo. This strategic outreach aligns with India’s positioning as a hub for affordable quality healthcare and medical tourism. By building international networks, Yatharth is creating new demand channels that can diversify revenue beyond domestic patients, adding resilience to its business model.

Strengthened Balance Sheet Through QIP

In December 2024, the company successfully completed a Qualified Institutional Placement (QIP) of ₹625 crore. This capital infusion not only strengthens the balance sheet but also provides the necessary funds to support capex-heavy expansion projects. With healthcare being a long-gestation business, such timely fundraises ensure adequate liquidity to sustain growth momentum.

Workforce Expansion

The company’s employee base, as measured by EPFO filings, grew significantly from 228 employees in September 2024 to 520 employees in May 2025, marking a 2.3x increase. This growth in headcount mirrors the company’s rapid operational expansion and readiness to manage increasing patient volumes across multiple facilities.

Red Flags and Risks

Despite the strong fundamentals, certain risks warrant attention:
Working capital days increased from 79 in FY23 to 123 in FY24, reflecting rising receivables and stretched cash cycles.
Promoter pledging – Promoters have pledged 13.8% of their stake, which raises governance concerns and exposes the company to potential risks if the pledges are invoked.
Management turnover – The resignation of Deepak Kumar Tyagi, President – Strategy and Finance, in March 2025 creates a gap in senior leadership and raises questions about continuity in strategic execution.

Summary of Fundamentals

30% revenue growth guidance for FY26 and beyond.
3,000 beds target by FY28 with multiple expansions underway.
Capex of ₹300–310 crore annually, with fixed assets up 37% YoY.
₹4,029 crore order book equivalent (through expansion and contracts in healthcare services).
International presence through information centers and ministry tie-ups.
₹625 crore QIP completed in Dec 2024 for growth funding.
Red flags: higher working capital days, pledged promoter shares, and senior management exit.

Conclusion

Yatharth Hospitals & Trauma Care Services combines strong revenue visibility, rapid expansion, international outreach, and a strengthened balance sheet to position itself as a high-growth healthcare provider. While the fundamentals are overwhelmingly positive, risks around working capital efficiency, promoter pledging, and leadership churn temper the otherwise strong growth narrative. The company remains fundamentally growth-oriented, with red flags that merit close monitoring.